$GMAB

$44.73 +$0.05 (0.1%) Live

$GMAB Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 62.4M shares outstanding

Who owns GMAB?

By type of holder

Institutions 100.0% Everyone else 0.0%

No insider has reported a holding in the last two years, so insiders are counted in "Everyone else".

Concentration Top 10 holders own 106.4%

Paradigm Biocapital Advisors LP 21.0% · Orbis Allan Gray Ltd 18.2%

Institutional ownership

100.0%

0 pts vs last qtr

Institutional holders

291

+15 vs last qtr

Net shares bought

+20.4M

by institutions in Q2 2026

New / sold out

48 / 33

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Paradigm Biocapital Advisors LP +5.2M
Deerfield Management Company, L.P. +4.4M

Biggest sellers in Q2 2026

Orbis Allan Gray Ltd −1.6M
Alliancebernstein L.P. −912.3K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Genmab A/S in the last 12 months.

Is your stake being diluted?

There are not yet two fiscal years of reported share counts for Genmab A/S.

How patient are the owners?

Institutional shares by how long they've been held

5+ years22% 3–5 years14% 1–3 years22% Under 1 year42%

Quarterly turnover

19.0%

of institutional shares changed hands

Top 10 managers, median time held

2 years

Super Investors

Investment managers reporting GMAB on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
PB Paradigm Biocapital Advisors LP	13.1M	21.04%	+5.2M (+64.8%)	Q3 '25	6.8%
Shares held by quarter Peak holding13.1M (Q2'26) Change over 8 quarters+13.1M Share of the company21.040% Paradigm Biocapital Advisors LP's full portfolio →
OA Orbis Allan Gray Ltd	11.4M	18.22%	−1.6M (−12.0%)	2024	1.1%
Shares held by quarter Peak holding14.4M (Q4'25) Change over 8 quarters+9.7M Share of the company18.220% Orbis Allan Gray Ltd's full portfolio →

Paradigm Biocapital Advisors LP

13.1M

% of company

21.04%

Change vs last qtr

+5.2M (+64.8%)

Held since

Q3 '25

Orbis Allan Gray Ltd

11.4M

% of company

18.22%

Change vs last qtr

−1.6M (−12.0%)

Held since

2024

28 more super investors behind a free account

See every manager holding Genmab A/S, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting GMAB on Form N-PORT; together they hold 21.3% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
HL Harding Loevner International Equity Portfolio Harding Loevner Funds Inc	$134M	466.8K	0.75%	1.06%	July 31, 2026
IB iShares Biotechnology ETF iShares Trust	$102M	3.7M	5.93%	1.12%	June 30, 2026

Harding Loevner International Equity Portfolio

Harding Loevner Funds Inc

Position value

$134M

% of company

0.75%

% of the fund

1.06%

As of

July 31, 2026

iShares Biotechnology ETF

iShares Trust

Position value

$102M

% of company

5.93%

% of the fund

1.12%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Genmab A/S and how much of the fund the position is.

Comments